Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 46725 results
Parion begins Phase II trial of P-1037 to treat cystic fibrosis
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, has begun enrollment of a phase 2 clinical trial of P-1037 in patients with Cystic Fibrosis (CF).
News
The transformative promise of patient centric R&D
By Ken Getz
Stakeholders throughout the drug development enterprise have caught the patient centricity bug and it is highly contagious.
News
Apricus launches Virirec in Spain to treat erectile dysfunction
Apricus Biosciences, a biopharmaceutical company advancing innovative medicines in urology and rheumatology, announced the launch of Virirec in Spain by Recordati.
News
EMD Serono begins co-promotion of Pfizer's cancer drug Xalkori in US
By PBR Staff Writer
Merck subsidiary EMD Serono as part of its global strategic alliance with Pfizer has started co-promoting the latter's anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) in the US.
News
Gilead to buy EpiTherapeutics for $65m
By PBR Staff Writer
US-based biopharmaceutical firm Gilead Sciences has signed a definitive agreement to acquire EpiTherapeutics, a Danish developer of cancer drugs, for $65m.
News
AbbVie gets FDA breakthrough therapy status for venetoclax to treat CLL
By PBR Staff Writer
AbbVie has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its investigational medicine venetoclax to treat chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
News
Lilly to build new innovation center in Cambridge, US
By PBR Staff Writer
Eli Lilly and Company is planning to build a new drug delivery and device innovation center in Cambridge, Massachusetts.
News
ViiV Healthcare starts Phase III program with dolutegravir/rilpivirine combination to treat HIV
By PBR Staff Writer
ViiV Healthcare has initiated a Phase III clinical trial program to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.
News
Alexion agrees to buy Synageva BioPharma for $8.4bn
By PBR Staff Writer
US-based biopharmaceutical firm Alexion has entered into an agreement to acquire Synageva BioPharma for about $8.4bn.
News
GlaxoSmithKline drops plans to sell ViiV HIV drugs unit
By PBR Staff Writer
British pharmaceuticals firm GlaxoSmithKline (GSK) has dropped plans to sell its stake in ViiV Healthcare, the HIV drugs business.
News
Prometic to develop C1 esterase inhibitor (C1-Inh) as next plasma-derived drug candidate
ProMetic Life Sciences has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of hereditary angioedema (HAE), a rare genetic disorder in which C1-INH is lacking.
News
OPKO Health takesover EirGen Pharma
OPKO Health is pleased to announce the acquisition of EirGen Pharma, a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the US, Canada, Japan, Australia, most European countries, and more than 40 others around the world.
News
Amarantus gets notice of allowance for USPTO covering proprietary compositions of matter and methods of use for MANF
Amarantus BioScience Holdings (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof."
News
CytoDyn submits Phase III protocol to FDA after agreement on protocol synopsis
CytoDyn, a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, has reached an agreement with the FDA on the Company's previously submitted Phase III protocol synopsis for PRO 140, the Company's novel self-injectable antibody for the treatment of HIV, and submitted the full Phase III protocol to the FDA today.
News
Abbvie reports positive results from Phase III trial of Humira
AbbVie has announced results from VISUAL‑I, a Phase III study investigating the efficacy and safety of Humira (adalimumab) in adult patients with active non-infectious intermediate, posterior, or panuveitis who still experienced intraocular inflammation while on systemic corticosteroid therapy.
News
136-150 of 46725 results